Literature DB >> 2403597

Treatment of experimental pyelonephritis in the monkey.

J A Roberts1, M B Kaack, G Baskin.   

Abstract

Previous studies show that chronic pyelonephritis and end stage renal disease may follow acute pyelonephritis in children and adolescents when improperly or inadequately treated. Our study shows that there is a significant decrease in renal function following untreated acute bacterial pyelonephritis due to nephron loss. The acute inflammatory response is responsible for much of the renal damage, although damage from renal ischemia is an additional significant factor. The present study used a combination of an antibiotic and a xanthine oxidase inhibitor (allopurinol) as compared to antibiotic therapy alone begun 72 hours after infection. Both were successful in eradicating the infection rapidly, but did not entirely prevent renal damage. Treatment prior to 72 hours thus is important. It appears that the combined treatment, designed to eradicate the bacteria as well as reduce the post-ischemic reperfusion damage and the phagocytic burst of phagocytosis is ideal, as this combined treatment was effective in preventing almost all renal damage and loss of renal function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403597     DOI: 10.1016/s0022-5347(17)39900-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Caffeic acid phenethyl ester suppresses oxidative stress in Escherichia coli-induced pyelonephritis in rats.

Authors:  Sefa Celik; Sadik Gorur; Ozkan Aslantas; Suat Erdogan; Sabahattin Ocak; Sibel Hakverdi
Journal:  Mol Cell Biochem       Date:  2006-10-19       Impact factor: 3.396

Review 2.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Effect of prednisolone on ascending renal infection due to biofilm disease and lower urinary tract obstruction in rats.

Authors:  M Haraoka; T Matsumoto; K Takahashi; S Kubo; M Tanaka; J Kumazawa
Journal:  Urol Res       Date:  1995

4.  Plasma and urinary soluble adhesion molecule expression is increased during first documented acute pyelonephritis.

Authors:  R A Gbadegesin; S A Cotton; B M Coupes; A Awan; P E C Brenchley; N J A Webb
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

5.  Protective anti-idiotype antibodies in the primate model of pyelonephritis.

Authors:  M B Kaack; L N Martin; S B Svenson; G Baskin; R H Steele; J A Roberts
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

6.  The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract.

Authors:  J A Roberts; B I Marklund; D Ilver; D Haslam; M B Kaack; G Baskin; M Louis; R Möllby; J Winberg; S Normark
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  The possible role of granulocyte elastase in renal damage from acute pyelonephritis.

Authors:  M Monga; J A Roberts
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

8.  Vitamin E administration at the onset of fever prevents renal scarring in acute pyelonephritis.

Authors:  Zhina Sadeghi; Abdol-Mohammad Kajbafzadeh; Parvin Tajik; Maryam Monajemzadeh; Seyedmehdi Payabvash; Azadeh Elmi
Journal:  Pediatr Nephrol       Date:  2008-06-04       Impact factor: 3.714

9.  Cytokine and lymphocyte activation during experimental acute pyelonephritis.

Authors:  J A Roberts; M B Kaack; L N Martin
Journal:  Urol Res       Date:  1995

10.  Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.

Authors:  James A Roberts; M Bernice Kaack; Gary Baskin; Matthew R Chapman; David A Hunstad; Jerome S Pinkner; Scott J Hultgren
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.